PD-L1 expression as a predictive biomarker in cancer immunotherapy

Cited by (1,001)

Items 601–700 of 1,001

1. NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy
   Leona Raskova Kafkova, Joanna Maria Mierzwicka, Prosenjit Chakraborty, Petr Jakubec, Ondřej Fischer, Jozef Škarda, Petr Malý, Milan Raška · 2024 · Frontiers in Immunology
2. Distinct Immunoregulatory Mechanisms in Mesenchymal Stem Cells: Role of the Cytokine Environment
   Vladimı́r Holáň, Barbora Heřmánková, Pavla Boháčová, Jan Kössl, Milada Chudíčková, Michaela Hájková, Magdaléna Krulová, Alena Zajı́cová, Eliška Javorková · 2016 · Stem Cell Reviews and Reports
3. Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan‐cancer survey with implications for the use of immune checkpoint inhibitors
   Jan Budczies, Michael Ludwig Bockmayr, Frederick Klauschen, Volker Endris, Stefan Fröhling, Peter Schirmacher, Carsten Denkert, Albrecht Stenzinger · 2017 · Genes Chromosomes and Cancer
4. Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns
   Mina Nikanjam, Harsh Patel, Razelle Kurzrock · 2017 · OncoImmunology
5. The kidney cancer research priority-setting partnership: Identifying the top 10 research priorities as defined by patients, caregivers, and expert clinicians
   Jennifer Michelle Jones, Jaimin R. Bhatt, Jonathan Avery, Andreas Laupacis, Katherine Cowan, Naveen S. Basappa, Joan Basiuk, Christina Canil, Sohaib Al-Asaaed, Daniel Yick Chin Heng et al. · 2017 · Canadian Urological Association Journal
6. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma
   Kyu Sang Lee, Kyoungyul Lee, Sumi Yun, Seyoung Moon, Yujun Park, Jung Ho Han, Chae‐Yong Kim, Hye Seung Lee, Gheeyoung Choe · 2017 · Journal of Neuro-Oncology
7. A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1: Validation in Mouse Models and Human Cancer Tissues
   Arutselvan Natarajan, Chirag B. Patel, Sindhuja Ramakrishnan, Paramjyot S. Panesar, Steven Long, Sanjiv Sam Gambhir · 2018 · Clinical Cancer Research
8. The Discovery of Biomarkers in Cancer Immunotherapy
   Anil P. George, Timothy Michael Kuzel, Yi Zhang, Bin Zhang · 2019 · Computational and Structural Biotechnology Journal
9. Expression of Immune Checkpoint Receptors on T-Cells and Their Ligands on Leukemia Blasts in Childhood Acute Leukemia
   Sung Han Kang, Hyun Ju Hwang, Jae Won Yoo, Hyery Kim, Eun Seok Choi, Sang‐Hyun Hwang, Young‐Uk Cho, Seongsoo Jang, Chan‐Jeoung Park, Ho Joon Im et al. · 2019 · Anticancer Research
10. Circulating Tumor Cells as a Biomarker to Assist Molecular Diagnosis for Early Stage Non-Small Cell Lung Cancer
    Yutong He, Jin Fa Shi, Bernd Schmidt, Qingyi Liu, Gaofeng Shi, Xiaoli Xu, Congmin Liu, Zhaoyu Gao, Tiantian Guo, Baoen Shan · 2020 · Cancer Management and Research
11. Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma
    Atsunari Kawashima, Takayuki Kanazawa, Yujiro Kidani, Tetsuya Yoshida, Michinari Hirata, Kentaro Nishida, Satoshi Nojima, Yoshiyuki Yamamoto, Taigo Kato, Koji Hatano et al. · 2020 · Scientific Reports
12. HIF1A expression correlates with increased tumor immune and stromal signatures and aggressive phenotypes in human cancers
    Baotao Chen, Lin Li, Mengyuan Li, Xiaosheng Wang · 2020 · Cellular Oncology
13. Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade
    Yu‐Ju Tseng, Chih‐Hung Lee, Wei‐Yu Chen, Jenq‐Lin Yang, Hong‐Tai Tzeng · 2021 · Journal of Investigative Dermatology
14. A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer
    Jianyuan Zhou, Sijuan Zou, Dong Kuang, Jianhua Yan, Jun Zhao, Xiaohua Zhu · 2021 · Frontiers in Oncology
15. PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance
    Jie Lian, Guanjun Zhang, Yun Zhang, Heng Liu, Jiaojiao Zhang, Pengfei Nan, Wei Tian · 2022 · Digestive and Liver Disease
16. Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
    Nicholas Bevins, Ryosuke Okamura, Meagan Montesion, Jacob J. Adashek, Aaron Michael Goodman, Razelle Kurzrock · 2022 · Journal of Immunotherapy and Precision Oncology
17. In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome
    Jeroen H. A. Creemers, Ankur Ankan, Kit C. B. Roes, Gijs Schröder, Niven Mehra, Carl Gustav Figdor, I. Jolanda M. de Vries, Johannes C. Textor · 2023 · Nature Communications
18. PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays
    Samuel Jacob Klempner, Eric S Cowden, Samuel Louis Cytryn, Matteo Fassan, Hisato Kawakami, Hideaki Shimada, Laura H. Tang, Daniel‐Christoph Wagner, Yasushi Yatabe, Alexander Savchenko et al. · 2024 · JCO Precision Oncology
19. Unlocking the Secrets of Extracellular Vesicles: Orchestrating Tumor Microenvironment Dynamics in Metastasis, Drug Resistance, and Immune Evasion
    Rashid Mir, Sadaf Khursheed Baba, Imadeldin Elfaki, Naseh A. Algehainy, Mohammad A. Alanazi, Faisal H. Altemani, Faris Jamal Tayeb, Jameel Barnawi, Eram Husain, Ruqaiah I. Bedaiwi et al. · 2024 · Journal of Cancer
20. Programmed Death Ligand 1 Expression in Paired Non–Small Cell Lung Cancer Tumor Samples
    Jong Ho Cho, Steffen Filskov Sorensen, Yoon‐La Choi, Yu Feng, Taeeun Kim, Heyjoo Choi, Jeanette Bæhr Georgsen, Marisa P Dolled-Filhart, Kenneth Emancipator, Peter Meldgaard et al. · 2017 · Clinical Lung Cancer
21. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine
    Hyunjoon Kim, Vidhi Khanna, Tamara A. Kucaba, Wenqiu Zhang, David M. Ferguson, Thomas S. Griffith, Jayanth Panyam · 2019 · Molecular Pharmaceutics
22. Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma?
    James J. Harding, Danny N. Khalil, Ghassan K. Abou‐Alfa · 2019 · Digestive Diseases and Sciences
23. Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
    Bettina Sobottka, Marta Nowak, Anja Laura Frei, Martina Haberecker, Samuel Merki, Mitchell Paul Levesque, Reinhard Dummer, Holger Moch, Viktor Hendrik Koelzer, Ruedi H. Aebersold et al. · 2021 · Laboratory Investigation
24. Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
    Fenglong Bie, He Tian, Nan Sun, Ruochuan Zang, Moyan Zhang, Peng Song, Lei Liu, Yue Peng, Guangyu Bai, Bolun Zhou et al. · 2022 · Frontiers in Oncology
25. Epigenetically modified AP-2α by DNA methyltransferase facilitates glioma immune evasion by upregulating PD-L1 expression
    Shengwen Long, Gui‐Xiang Huang, Mi Ouyang, Kai Xiao, Hao Zhou, Anyi Hou, Zhiwei Li, Zhe Zhong, Dongmei Zhong, Qinghao Wang et al. · 2023 · Cell Death and Disease
26. Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening
    Katarzyna Ratajczak, Hubert Grel, Piotr Olejnik, Sławomir Jakieła, Magdalena Stobiecka · 2023 · Biosensors and Bioelectronics
27. Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP 142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system
    Kelly Schats, Emily A. Van Vré, Stefanie De Schepper, Carolien Boeckx, Dorien M. Schrijvers, Wim Waelput, Erik Fransén, Isabelle Vanden Bempt, Bart Neyns, Ingrid De Meester et al. · 2016 · Histopathology
28. Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database
    Abdul Rafeh Naqash, Chipman Robert Geoffrey Stroud, Muhammad Butt, Grace Kho Dy, Aparna Madhukeshwar Hegde, Mahvish Muzaffar, Li V. Yang, Maida Hafiz, Cynthia R. Cherry, Paul R. Walker · 2017 · Acta Oncologica
29. Immunotherapy for Esophageal Cancer: A 2019 Update
    Dimitriοs Schizas, Nikolaos Charalampakis, Christo Kole, Konstantinos S. Mylonas, Ioannis Katsaros, Meina Zhao, Jaffer A. Ajani, Amanda K. Psyrri, Michalis V. Karamouzis, Theodore Liakakos · 2020 · Immunotherapy
30. Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer
    Chaoyan Wang, Menghan Weng, Shuli Xia, Min Zhang, Chaoyi Chen, Jinlong Tang, Dan Huang, Hongfei Yu, Wenjie Sun, Honghe Zhang et al. · 2020 · Cancer Science
31. Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
    Mohamed Eltahir, Johan Isaksson, Johanna Sofia Margareta Mattsson, Klas Kärre, Johan Botling, Martin Lord, Sara M. Mangsbo, Patrick Micke · 2021 · Cancers
32. Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy
    Panagiota Maravelia, Daniela Nascimento Silva, Giulia Rovesti, Michael Chrobok, Per I Stal, Yong‐Chen Lu, Anna Pasetto · 2021 · Cancers
33. Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti–programmed cell death protein‐1 therapy
    Hongxi Wu, Li Yan, Guangjiang Shi, Shijia Du, Xiaobin Wang, Wanli Ye, Zixuan Zhang, Ya Chu, Shuqian Ma, Dajia Wang et al. · 2022 · Hepatology
34. Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma
    Jianping Gui, Zhen Guo, Di Wu · 2022 · Journal of Translational Medicine
35. Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
    Durre Aden, Samreen Zaheer, Niti Sureka, Monal Trisal, Jai Kumar Chaurasia, Sufian Zaheer · 2025 · Pathology - Research and Practice
36. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics
    Philip R. Cohen, Brett N. Tomson, Sheryl Krevsky Elkin, Erica Marchlik, Jennifer L. Carter, Razelle Kurzrock · 2016 · Oncotarget
37. Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
    Philip R. Cohen, Shumei Kato, Aaron Michael Goodman, Sadakatsu Ikeda, Razelle Kurzrock · 2017 · International Journal of Molecular Sciences
38. Microsatellite instability in endometrial cancer: New purpose for an old test
    Katherine C. Kurnit, Shannon Neville Westin, Robert Louis Coleman · 2019 · Cancer
39. Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
    Kyung Hwan Kim, Chang Gon Kim, Eui‐Cheol Shin · 2020 · Immune Network
40. Modulating tumor immunity by metronomic dosing of oxaliplatin incorporated in multiple oral nanoemulsion
    Jeong Uk Choi, Ruby Maharjan, Rudra Pangeni, Saurav Kumar Jha, Na Kyeong Lee, Seho Kweon, Ha Kyeong Lee, Kwan-Young Chang, Young Kweon Choi, Jin Woo Park et al. · 2020 · Journal of Controlled Release
41. Erratum: Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade.
    Hongzhi Li, Weihua Yuan, Shufang Bin, Guang Jer Wu, Panyuan Li, Min Liu, Jifeng Yang, Xiang Li, Kaiyan Yang, Haihua Gu · 2020 · PubMed Central
42. Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma
    Dominic M. Maggio, Winson S. Ho, Rebecca Breese, Stuart Walbridge, Herui Wang, Jing Cui, John D. Heiss, Mark R. Gilbert, John S. Kovach, Rongze Olivia. Lu et al. · 2020 · Journal of Neuro-Oncology
43. Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma
    Fucun Xie, Yi Bai, Xu Yang, Junyu Long, Jinzhu Mao, Jianzhen Lin, Dongxu Wang, Yang Song, Ziyu Xun, Hanchan Huang et al. · 2020 · International Immunopharmacology
44. Effect of cryopreservation on delineation of immune cell subpopulations in tumor specimens as determined by multiparametric single cell mass cytometry analysis
    Elma Kadić, Raymond J. Moniz, Ying Huo, An Chi, Ilona Kariv · 2017 · BMC Immunology
45. Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospects
    Maximilian Boesch, Lena Horvath, Florent Baty, Andreas Pircher, Dominik Georg Friedrich Wolf, Stephan Spahn, Ravid Straussman, Herbert Tilg, Martin Hugo Brutsche · 2022 · Journal for ImmunoTherapy of Cancer
46. CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer
    Asa P. Y. Lau, Sharon S. Khavkine Binstock, Kelsie L. Thu · 2023 · Cancers
47. Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients
    Abdullah Y. Al-Danakh, Mohammed Safi, Yuli Jian, Linlin Yang, Xinqing Zhu, Qiwei Chen, Kangkang Yang, Shujing Wang, Jianjun Zhang, Deyong Yang · 2024 · Frontiers in Immunology
48. Prognostic Biomarkers in Evolving Melanoma Immunotherapy
    Robin Reschke, Alexander Heinrich Enk, Jessica C. Hassel · 2024 · American Journal of Clinical Dermatology
49. Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations
    Michael P Castro, Neal S. Goldstein · 2015 · Journal for ImmunoTherapy of Cancer
50. SCHLAFEN 5 expression correlates with intestinal metaplasia that progresses to gastric cancer
    Osmel Companioni, Amy C. Tsao, José Miguel Sanz Anquela, Núria Sala, Catalina Bonet, María Luisa Pardo, Lin Ding, Ornella Simo, Milena Saqui–Salces, Verónica Parra Blanco et al. · 2016 · Journal of Gastroenterology
51. Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer
    Wesley Baas, Svetlana Gershburg, Danuta I. Dynda, Kristin R. Delfino, Kathy Robinson, Daotai Nie, Jennifer Holmes Yearley, Shaheen Riadh Alanee · 2017 · Clinical Genitourinary Cancer
52. Exploration of the Combination of PLK1 Inhibition with Immunotherapy in Cancer Treatment
    Mengyuan Li, Zhixian Liu, Xiaosheng Wang · 2018 · Journal of Oncology
53. Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
    Zhi Ji, Zhi Peng, Jifang Gong, Xiaotian Zhang, Jian Li, Ming Shian Lu, Zhihao Lü, Lin Shen · 2019 · BMC Cancer
54. Atezolizumab: A Review in Extensive-Stage SCLC
    James E. Frampton · 2020 · Drugs
55. Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer.
    Junyoung Choi, Hee Jin Lee, Shinkyo Yoon, Hyun-Min Ryu, Eunjin Lee, Yujin Jo, Seyoung Seo, Deokhoon Kim, Chang Hoon Lee, Wanlim Kim et al. · 2020 · PubMed Central
56. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer
    Colt A. Egelston, Weihua Guo, Susan Elaine Yost, Jin Sun Lee, David L. Rose, Christian Avalos, Jian Ye, Paul Henry Frankel, Daniel D. Schmolze, James Ross Waisman et al. · 2021 · Journal for ImmunoTherapy of Cancer
57. How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy
    Adam Michael Fundytus, Christopher M. Booth, Ian F. Tannock · 2021 · Annals of Oncology
58. miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma
    Anup Singh Pathania, Philip Prathipati, Omalla Allan Olwenyi, Srinivas Prabhu Chava, Oghenetejiri V. Smith, Subash C. Gupta, Nagendra K. Chaturvedi, Siddappa N. Byrareddy, Donald W. Coulter, Kishore B. Challagundla · 2022 · Molecular Therapy — Oncolytics
59. Module Analysis Captures Pancancer Genetically and Epigenetically Deregulated Cancer Driver Genes for Smoking and Antiviral Response
    Magali Champion, Kevin Brennan, Tom Croonenborghs, Andrew J. Gentles, Nathalie L.M.M. Pochet, Olivier Gevaert · 2017 · EBioMedicine
60. Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness
    Aaron Michael Goodman, Shumei Kato, Ranajoy Chattopadhyay, Ryosuke Okamura, Ila Maewal Saunders, Meagan Montesion, Garrett Michael Frampton, Vincent A. Miller, Gregory A. Daniels, Razelle Kurzrock · 2019 · Cancer Immunology Research
61. Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review
    Juan Carlos Restrepo, Darly Martínez Guevara, Andrés Pareja López, John Fernando Montenegro Palacios, Yamil Liscano · 2024 · Cancers
62. PI3K/AKT/mTOR and PD‑1/CTLA‑4/CD28 pathways as key targets of cancer immunotherapy (Review)
    Shuangcui Wang, Changyu Liu, Chenxin Yang, Yutong Jin, Qian Cui, Dong Wang, Ting Ge, Guixin He, Wentao Li, Guan Zhang et al. · 2024 · Oncology Letters
63. CD 274 ( PDL 1) and JAK 2 genomic amplifications in pulmonary squamous‐cell and adenocarcinoma patients
    Sergi Clavé, Lara Pijuán, David Casadevall, Álvaro Taus, Javier Gimeno, Silvia Hernández‐Llodrà, María Rodríguez‐Rivera, Marta Lorenzo, Sílvia Menéndez, Joan Albanell et al. · 2017 · Histopathology
64. Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis
    Yi Ming Weng, Min Peng, Meng Xue Hu, Yi Yao, Qi Bin Song · 2018 · OncoTargets and Therapy
65. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment
    Davide Busato, Monica Mossenta, Lorena Baboçi, Federica Di Cintio, Giuseppe Toffoli, Michele Dal Bo · 2019 · Expert Review of Clinical Pharmacology
66. First report on two cases of pleomorphic dermal sarcoma successfully treated with immune checkpoint inhibitors
    Sebastian Klein, Oana‐Diana Persa, Cornelia Mauch, Ka‐Won Noh, Roberto Pappesch, Svenja Wagener‐Ryczek, Reinhard Buettner, Alexander Quaas, Doris Helbig · 2019 · OncoImmunology
67. PD‐L1 and thyroid cytology: A possible diagnostic and prognostic marker
    Marco Dell’Aquila, Alessia Granitto, Maurizio Martini, Sara Capodimonti, Alessandra Cocomazzi, Teresa Musarra, Vincenzo Fiorentino, Alfredo Pontecorvi, Celestino Pio Lombardi, Guido Fadda et al. · 2019 · Cancer Cytopathology
68. The Impact of Estrogen in the Tumor Microenvironment
    Ashwin Somasundaram, Natalie J. Rothenberger, Laura P. Stabile · 2020 · Advances in experimental medicine and biology
69. Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer
    Jeong Uk Lim, Hyoung Kyu Yoon · 2020 · Cytokine
70. SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
    Siwen Hu‐Lieskovan, Srabani Bhaumik, Kavita M. Dhodapkar, Jean‐Charles Grivel, Sumati V. Gupta, Brent Allen Hanks, Sylvia Janetzki, Thomas O. Kleen, Yoshinobu Koguchi, Amanda W. Lund et al. · 2020 · Journal for ImmunoTherapy of Cancer
71. Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors
    Quoc D. Mac, Anirudh Sivakumar, Hathaichanok Phuengkham, Congmin Xu, James R. Bowen, Fang‐Yi Su, Samuel Z. Stentz, Hyoungjun Sim, Adrian M. Harris, Tonia T. Li et al. · 2022 · Nature Biomedical Engineering
72. Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma
    Da‐Liang Ou, Yuyang Lin, Chia‐Lang Hsu, Yinyao Lin, Chia‐Wei Chen, Jhang-Sian Yu, Shi‐Chuen Miaw, Ping‐Ning Hsu, Ann‐Lii Cheng, Chiun Hsu · 2018 · Liver Cancer
73. APC mutation correlated with poor response of immunotherapy in colon cancer
    Bing Li, Guoliang Zhang, Xuejie Xu · 2023 · BMC Gastroenterology
74. BCLAF1 binds SPOP to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinoma
    Zongdong Yu, Xiang Wu, Jie Zhu, Huan Yan, Yuxuan Li, Hui Zhang, Yeling Zhong, Man Lin, Ganghui Ye, Xinming Li et al. · 2024 · Cellular and Molecular Life Sciences
75. The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC)
    Che-Wei Wang, Pulak Kumar Biswas, Atikul Islam, Mu‐Kuan Chen, Pin Ju Chueh · 2024 · Cells
76. Artificial intelligence-based digital pathology using H&E-stained whole slide images in immuno-oncology: from immune biomarker detection to immunotherapy response prediction
    Jessica Zhang, Horyun Choi, Yeseul Kim, Jonghanne Park, Sukjoo Cho, Eugene Kim, Allen Cho, Ju Young Lee, Jaeyoun Choi, Christmann Low et al. · 2025 · Journal for ImmunoTherapy of Cancer
77. Immune Checkpoint Inhibitors in Lung Cancer: Past, Present and Future
    Nagashree Seetharamu, Daniel R. Budman, Kevin M. Sullivan · 2016 · Future Oncology
78. Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma
    Yingfei Li, Jian-Wu Ding, Ling-Min Liao, Zhilin Zhang, Shousheng Liao, Ying Wu, Dan-Yang Zhou, Anwen Liu, Long Huang · 2017 · Molecular and Clinical Oncology
79. JQ1, a BET‐bromodomain inhibitor, inhibits human cancer growth and suppresses PD‐L1 expression
    Kaisheng Liu, Zhifan Zhou, Hengyuan Gao, Fang Yang, Yajun Qian, Hongtao Jin, Yaomin Guo, Ying Liu, Haili Li, Cheng Zhang et al. · 2019 · Cell Biology International
80. Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice
    Michela Roberto, Andrea Botticelli, Martina Panebianco, Anna Maria Aschelter, Alain Jonathan Gelibter, Chiara Ciccarese, Mauro Minelli, Marianna Nuti, Daniele Santini, Andrea Laghi et al. · 2021 · Frontiers in Oncology
81. Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response
    Sarabjot Pabla, Robert J. Seager, Erik Van Roey, Shuang Gao, Carrie Hoefer, Mary Nesline, Paul DePietro, Blake Burgher, Jonathan Andreas, Vincent Giamo et al. · 2021 · Biomarker Research
82. A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE
    Jian Zhang, Huizhong Li, Da-Zhi Gao, Baofu Zhang, Maojin Zheng, Mingyin Lun, Meng‐Xue Wei, Rui Duan, Maomao Guo, Jiajun Hua et al. · 2018 · Cancer Biology & Therapy
83. PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population
    Kihwan Hwang, Eun Jung Koh, Eun Jin Choi, Tae Hee Kang, Jung Ho Han, Gheeyoung Choe, Sung‐Hye Park, Jennifer Holmes Yearley, Lakshmanan Annamalai, Wendy M. Blumenschein et al. · 2018 · Journal of Neuro-Oncology
84. Combining radiation therapy and cancer immune therapies: From preclinical findings to clinical applications
    S. Bockel, B. Durand, Éric Deutsch · 2018 · Cancer/Radiothérapie
85. Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers
    Andrew Meci, Neerav Goyal, Guy Slonimsky · 2024 · Cancers
86. Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma
    Karishma R. Rajani, Lucas P. Carlstrom, Ian F. Parney, Aaron J. Johnson, Arthur E. Warrington, Terry C. Burns · 2019 · Frontiers in Oncology
87. Digital quantitative assessment of PD-L1 using digital spatial profiling
    Swati Gupta, Jon Zugazagoitia, Sandra Martínez-Morilla, Kit A. Fuhrman, David L. Rimm · 2020 · Laboratory Investigation
88. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1
    Daniel J. Rubins, Xiangjun Meng, Paul S. Mcquade, Michael T. Klimas, Krista L. Getty, Shu-An Lin, Brett Connolly, Stacey S O'Malley, Hyking Haley, Mona L. Purcell et al. · 2020 · Molecular Imaging and Biology
89. GREB1L overexpression correlates with prognosis and immune cell infiltration in lung adenocarcinoma
    Yilin Yu, Zhiping Wang, Qunhao Zheng, Jiancheng Li · 2021 · Scientific Reports
90. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
    Matthew K. Stein, Oluchukwu Oluoha, Kruti Patel, Ari M. Vanderwalde · 2021 · Journal of Personalized Medicine
91. PD-L1 Expression as a Predictive Biomarker For Immune Checkpoint Inhibitors: Between a Dream And a Nightmare
    Joseph Zouein, Carole Kesrouani, Hampig Raphaël Kourié · 2021 · Immunotherapy
92. Identification and validation of a novel signature for prediction the prognosis and immunotherapy benefit in bladder cancer
    Yichi Zhang, Yifeng Lin, Daojun Lv, Xiangkun Wu, Wenjie Li, Xueqing Wang, Dongmei Jiang · 2022 · PeerJ
93. Fatty Acids as a Tool to Boost Cancer Immunotherapy Efficacy
    Annemarie J. F. Westheim, Lara M. Stoffels, Ludwig Jerome Dubois, Jeroen van Bergenhenegouwen, Ardy van Helvoort, RAMON C. J. LANGEN, Ronit Shiri‐Sverdlov, Jan Theys · 2022 · Frontiers in Nutrition
94. A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation
    Weston L. Daniel, Ulrike Lorch, Scott Mix, Alice Susannah Bexon · 2022 · Frontiers in Immunology
95. Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system
    Giulia Grizzi, Mario Caccese, Αναστάσιος Γκουντάκος, Luisa Carbognin, Giampaolo Tortora, Emilio Bria, Sara Pilotto · 2017 · Expert Review of Molecular Diagnostics
96. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies
    Giandomenico Roviello, Fabrice André, Sergio Venturini, Barbara Pistilli, Giuseppe Curigliano, Massimo Cristofanilli, Pietro Rosellini, Daniele Generali · 2017 · European Journal of Cancer
97. Advances in Melanoma: From Genetic Insights to Therapeutic Innovations
    Fernando Valdez-Salazar, Luis A. Jiménez-Del Rio, Jorge Ramón Padilla‐Gutiérrez, Yeminia Valle, José Francisco Muñóz-Valle, Emmanuel Valdés‐Alvarado · 2024 · Biomedicines
98. Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2
    Alireza Tojjari, Yassine Alami Idrissi, Anwaar Saeed · 2024 · Cancer Letters
99. Human Monocytic Suppressive Cells Promote Replication of Mycobacterium tuberculosis and Alter Stability of in vitro Generated Granulomas
    Neha Agrawal, Ioana Streață, Gang Pei, January Mikolaj Weiner, Leigh A. Kotzé, Silke Bandermann, Laura Lozza, Gerhard Walzl, Nelita du Plessis, Mihai I. Ioana et al. · 2018 · Frontiers in Immunology
100. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma
     Willem J. Koemans, Myriam Chalabi, Johanna Wilhelmina van Sandick, Jolanda M. van Dieren, Liudmila L. Kodach · 2018 · Cancer Letters